UPDATE: Chambre, Celera s Erstwhile COO, Tapped to Run CAT | GenomeWeb

NEW YORK, Feb. 25 - Peter Chambre, Celera's former chief operating officer, will become CEO of Cambridge Antibody Technology, CAT said on Monday. He is slated to start sometime in April.

"We are delighted that Peter has agreed to join CAT at this time when the company is positioning itself for transition to a profitable biopharmaceutical business," Peter Garland, CAT's chairman, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.